Blueprint Medicines

Blueprint Medicines is a biopharmaceutical company focused on developing medicines for patients with genomically defined cancers and rare diseases. The company's drug candidates are: avapritinib, its key drug candidate, which is an orally available and selective inhibitor that targets KIT and PDGFRa mutations; BLU-554, an orally available and selective inhibitor that targets FGFR4, a kinase that is aberrantly activated in a defined subset of patients with hepatocellular carcinoma, a type of liver cancer; and BLU-667, which targets RET, a receptor tyrosine kinase that is abnormally activated by mutations or translocations, and RET resistance mutations.
  • TickerBPMC
  • ISINUS09627Y1091
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for BPMC

ValuEngine Rating and Forecast Report for BPMC

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

ValuEngine Rating and Forecast Report for BPMC

ValuEngine Rating and Forecast Report for BPMC

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

ValuEngine Rating and Forecast Report for BPMC

ValuEngine Rating and Forecast Report for BPMC

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

David Nierengarten ...
  • Jeffrey La Rosa

Doctor Call: Avapritinib Looks to Stay Ahead in Mastocytosis

2 directors sold

Two Directors at Blueprint Medicines Corp sold 25,568 shares at between 90.000USD and 90.360USD. The significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under lis...

ValuEngine Rating and Forecast Report for BPMC

ValuEngine Rating and Forecast Report for BPMC

ValuEngine Rating and Forecast Report for BPMC

ValuEngine Rating and Forecast Report for BPMC

ValuEngine Rating and Forecast Report for BPMC

ValuEngine Rating and Forecast Report for BPMC

ValuEngine Rating and Forecast Report for BPMC

ValuEngine Rating and Forecast Report for BPMC

ValuEngine Rating and Forecast Report for BPMC

ValuEngine Rating and Forecast Report for BPMC

ResearchPool Subscriptions

Get the most out of your insights

Get in touch